Last reviewed · How we verify

NCT04659356: NOSOCOVID

NOSOcomial COVID-19 in ICU (NOSOCOVID)

Status unknown Last updated 23 March 2021
What this trial tests

trial testing Patients admitted in Intensive Care Units in Coronavirus Infectious Disease (COVID-19) in 600 participants. Status unknown.

Timeline
1 September 2020
Primary endpoint
1 July 2021
14 July 2021

Quick facts

Lead sponsorNantes University Hospital
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment600
Start date1 September 2020
Primary completion1 July 2021
Estimated completion14 July 2021
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Nantes University Hospital

Who can join

18 and older, any sex, with Coronavirus Infectious Disease (COVID-19) or Nosocomial Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The current global pandemic at COVID-19 is a major public health issue. Transmission of the virus is primarily through direct and close person-to-person contact. The protection of health care personnel and the limitation of transmission of nosocomial COVID is paramount. Protective measures have already shown their effectiveness in limiting the spread of the virus: the use of masks, the wearing of protective gowns, the wearing of protective eyewear, social and physical distancing. A recent U.S. study (Rhee et al. JAMA 2020) reported a very low incidence of 1.7% of nosocomial COVID, but this was achieved with the application of rigorous infection risk management protocols. In addition to the widespread use of masks and protective measures, dedicated COVID units had been created, with air treatment. The implementation of these dedicated units requires the mobilization of considerable human and material resources, which is not feasible in all hospitals over the long term. In view of the second wave of the epidemic in France, with the rising numbers of new cases of COVDI-19 admitted to intensive care units since the end of the summer 2020, it is essential to organize the intensive care units to ensure the protection of personnel and limit the risk of nosocomial COVID-19, while continuing to care for non-COVID patients. In Intensive Care unit (ICU) at the Nantes University Hospital, a strict protocol for the management of suspected or confirmed COVID patients has been in place since early september 2020. The objective of this study is to evaluate the effectiveness of this protocol for managing the infectious risk of SARS-COV-2 on the incidence of nosocomial COVID in patients admitted in ICU. The secondary objectives are to evaluate the incidence of nosocomial-associated COVIDs contracted by caregivers, and the incidence of asymptomatic positive SARS-CoV-2 cases in ICU.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Nantes University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04659356.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing